Depo-Provera and Meningioma: What the FDA's 2024 Warning Means for You
Last updated:
For more than 30 years, Depo-Provera was marketed as a safe and effective contraceptive with few serious side effects. Then in August 2024, the FDA did something it rarely does: it added a black box warning — the strongest safety label in American medicine — linking the drug to brain tumor growth. Here's what that warning says, what it doesn't say, and why it matters for millions of women who used the shot.
What the FDA Changed in August 2024
On August 5, 2024, the FDA updated the prescribing information for medroxyprogesterone acetate injectable suspension (brand name: Depo-Provera, manufactured by Pharmacia & Upjohn, a Pfizer subsidiary) to include a black box warning about intracranial meningioma.
The warning specifically states that prolonged use of injectable MPA is associated with an increased risk of meningioma — a tumor arising from the meninges, the protective membrane layers surrounding the brain. The FDA directed that Depo-Provera should be discontinued if meningioma is diagnosed.
This wasn't a sudden discovery. The agency had been reviewing European data for years. France's ANSM (National Agency for Medicine Safety) had flagged the association in 2018. A major French cohort study published in the BMJ in February 2024 — analyzing 18,061 women with intracranial meningioma — documented a 5.6-fold increased risk in women with the highest cumulative exposure to injectable MPA.
That BMJ study triggered the formal FDA action. Three months after publication, the black box warning was official.
What a Black Box Warning Actually Means
The FDA issues black box warnings (formally: boxed warnings) only when clinical studies show a drug can cause serious or life-threatening adverse effects. As of 2024, fewer than 400 drugs carry one. This isn't routine language. When the FDA puts information in a black box, it means the evidence of harm cleared the highest regulatory threshold for required disclosure.
For context: the original Depo-Provera labeling had warnings about bone density loss (another serious long-term concern), but nothing about tumors. Women who used the shot between the 1990s and 2024 made contraceptive decisions without this information.
That gap — between when the science emerged and when the warning was issued — is precisely where the litigation lives. Plaintiffs' attorneys argue that Pfizer had access to the same emerging European data that regulators did, and chose not to update warnings proactively.
The MPA Concentration Data
Medroxyprogesterone acetate (MPA) is a synthetic progestogen, and the injectable formulation delivers it at concentrations that oral progestogens simply cannot match. That distinction matters clinically.
Depo-Provera comes in two formulations: 150 mg/mL (the standard contraceptive dose, given every 13 weeks) and 400 mg/mL (the higher-dose formulation used for endometriosis and certain cancers). The 2024 FDA warning covers both, but the risk profile differs by exposure level.
MPA binds to progesterone receptors, which are expressed in approximately 70% of meningiomas. This receptor binding is the proposed biological mechanism: sustained, high-concentration progesterone signaling may stimulate tumor growth in susceptible individuals. Several studies have documented that meningiomas in women who used high-dose progestogens are larger, more likely to be multiple, and more likely to require surgery than sporadic meningiomas in the general population.
The BMJ 2024 study quantified cumulative dose as the key variable. Women who had received the equivalent of 18 or more injections of the standard 150 mg/mL formulation showed dramatically elevated risk compared to women with 1 to 5 injections. That's roughly 4+ years of continuous use at the highest risk tier.
Key Data Points: FDA Warning and MPA Research
- FDA black box warning issued: August 5, 2024
- BMJ 2024 study: 5.6x increased meningioma risk with prolonged injectable MPA use
- Meningiomas express progesterone receptors in ~70% of cases
- French cohort studied: 18,061 women with intracranial meningioma vs. 90,305 matched controls
- Both Depo-Provera formulations (150 mg/mL and 400 mg/mL) covered by warning
- FDA directive: discontinue Depo-Provera if meningioma is diagnosed
Who Is at Risk
Not every woman who received a Depo-Provera injection will develop a meningioma. The elevated risk is concentrated in several identifiable groups.
Duration of use matters most. Women who used Depo-Provera continuously for two or more years are in the higher-risk category. The longer the use, the higher the cumulative MPA exposure, and the more pronounced the association in the research literature.
Age and hormonal context are secondary factors. Most meningiomas are diagnosed between ages 40 and 70. Women who started long-term Depo-Provera use in their 20s and 30s may be in the age window for symptomatic presentation now, decades later. The latency period between exposure and tumor diagnosis complicates the picture — and the litigation. (For a full discussion of the timeline question, see our piece on how long after stopping Depo-Provera meningioma can develop.)
No screening protocol exists. There is currently no FDA-recommended screening regimen for women with prior Depo-Provera use. Meningiomas are typically discovered incidentally on MRI or CT scans ordered for unrelated reasons, or when symptoms become severe enough to prompt imaging. Common symptoms include persistent headaches, vision changes, hearing loss, and cognitive difficulties. The meningioma symptoms page covers these in detail.
Women who used the 400 mg/mL formulation for endometriosis or other indications often received higher cumulative doses than contraceptive users, and may face even greater risk exposure.
What You Should Do Now
If you used Depo-Provera for two or more years and have experienced persistent headaches, vision problems, hearing changes, or cognitive symptoms, the logical first step is to talk to your doctor about neuroimaging. Don't wait for symptoms to worsen.
If you've already been diagnosed with a meningioma, the question of whether your Depo-Provera use contributed is worth exploring with a legal professional. The 2024 FDA warning makes it significantly easier to establish the scientific link in litigation, but individual cases still require documentation of use history, diagnosis records, and expert review.
As of April 2026, more than 1,700 cases have been filed in MDL 3140, consolidated before Judge John Z. Lee in the Northern District of Illinois. The first bellwether trials are being selected. Read our full MDL 3140 update for the current litigation timeline.
Statutes of limitations vary by state. In most jurisdictions, the clock starts when a plaintiff knew or reasonably should have known of the connection between their Depo-Provera use and their diagnosis — a date that often ties to the August 2024 FDA warning. But don't assume that means you have until 2026 or 2027 to decide. Check your state's specific rules with an attorney now.
Were You Affected by Depo-Provera?
If you used Depo-Provera for two or more years and were diagnosed with meningioma, you may have legal options. Our eligibility check takes under 2 minutes.
Get a Free Case Review →Related Resources
- What Is a Meningioma? Symptoms, Causes, Treatment
- MDL 3140: The Depo-Provera Litigation Hub
- Depo-Provera Side Effects: Full List
- How Long After Stopping Can Meningioma Develop?
- MDL 3140 Update: April 2026
Frequently Asked Questions
The FDA added a black box warning to Depo-Provera (medroxyprogesterone acetate injectable) in August 2024, stating that prolonged use is associated with an increased risk of meningioma. The warning applied to both the 150 mg/mL contraceptive formulation and the 400 mg/mL higher-dose formulation. It directed physicians to discontinue the drug if a meningioma is diagnosed in a patient using it.
Women who used Depo-Provera for two or more years face the highest documented risk. The BMJ 2024 study found up to a 5.6-fold increased risk in the highest cumulative exposure group (18+ injections at the 150 mg/mL dose). Risk appears to be dose-dependent: longer use and higher concentrations correlate with higher rates of tumor development.
Yes. The 2024 FDA black box warning strengthens existing litigation because it documents that the meningioma link crossed the regulatory threshold for required disclosure. Many plaintiffs argue the warning came years too late. Cases are being consolidated in MDL 3140 in the Northern District of Illinois. Use our eligibility checker to learn whether you may qualify.
The injectable formulation delivers MPA at concentrations that oral contraceptives do not. Oral progestogen-only pills use much lower doses and different progestogens. The current research specifically implicates high-dose, long-acting injectable MPA, not low-dose oral contraceptives. Women who used only birth control pills are not the focus of the current litigation.
Disclaimer: This article is for informational purposes only and does not constitute legal or medical advice. Information about litigation is current as of April 2026 and may change. Consult a qualified attorney and your physician for advice specific to your situation.